175 related articles for article (PubMed ID: 38075057)
1. The role of bone modifying agents for secondary osteoporosis prevention and pain control in post-menopausal osteopenic breast cancer patients undergoing adjuvant aromatase inhibitors.
Galvano A; Gristina V; Scaturro D; Bazan Russo TD; Tomasello S; Vitagliani F; Carità F; La Mantia M; Fulfaro F; Bazan V; Mauro GL; Russo A
Front Endocrinol (Lausanne); 2023; 14():1297950. PubMed ID: 38075057
[TBL] [Abstract][Full Text] [Related]
2. Predictive factors for the efficacy of denosumab in postmenopausal Japanese women with non-metastatic breast cancer receiving adjuvant aromatase inhibitors: a combined analysis of two prospective clinical trials.
Nakatsukasa K; Koyama H; Ouchi Y; Sakaguchi K; Fujita Y; Matsuda T; Kato M; Konishi E; Taguchi T
J Bone Miner Metab; 2019 Sep; 37(5):864-870. PubMed ID: 30868270
[TBL] [Abstract][Full Text] [Related]
3. Early Denosumab for the prevention of osteoporotic fractures in breast cancer women undergoing aromatase inhibitors: A case-control retrospective study.
Scaturro D; de Sire A; Terrana P; Curci C; Vitagliani F; Falco V; Cuntrera D; Iolascon G; Mauro GL
J Back Musculoskelet Rehabil; 2022; 35(1):207-212. PubMed ID: 34092604
[TBL] [Abstract][Full Text] [Related]
4. Effect of denosumab on low bone mineral density in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: 24-month results.
Nakatsukasa K; Koyama H; Ouchi Y; Ono H; Sakaguchi K; Matsuda T; Kato M; Ishikawa T; Yamada K; Yoshimura M; Koizumi K; Sakurai T; Shigematsu H; Takahashi S; Taira S; Suzuki M; Narui K; Niikura N; Hasegawa Y; Miura D; Konishi E; Taguchi T;
Breast Cancer; 2019 Jan; 26(1):106-112. PubMed ID: 30054855
[TBL] [Abstract][Full Text] [Related]
5. Effects of denosumab on bone mineral density in Japanese women with osteoporosis treated with aromatase inhibitors for breast cancer.
Nakatsukasa K; Koyama H; Ouchi Y; Sakaguchi K; Fujita Y; Matsuda T; Kato M; Konishi E; Taguchi T
J Bone Miner Metab; 2019 Mar; 37(2):301-306. PubMed ID: 29520506
[TBL] [Abstract][Full Text] [Related]
6. Quantitative ultrasound and DXA measurements in aromatase inhibitor-treated breast cancer women receiving denosumab.
Catalano A; Gaudio A; Morabito N; Basile G; Agostino RM; Xourafa A; Atteritano M; Morini E; Natale G; Lasco A
J Endocrinol Invest; 2017 Aug; 40(8):851-857. PubMed ID: 28332172
[TBL] [Abstract][Full Text] [Related]
7. Treatment of osteoporosis secondary to hypogonadism in prostate cancer patients: a prospective randomized multicenter international study with denosumab vs. alendronate.
Doria C; Mosele GR; Solla F; Maestretti G; Balsano M; Scarpa RM
Minerva Urol Nefrol; 2017 Jun; 69(3):271-277. PubMed ID: 27813398
[TBL] [Abstract][Full Text] [Related]
8. Effect of denosumab administration on low bone mineral density (T-score -1.0 to -2.5) in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer.
Nakatsukasa K; Koyama H; Ouchi Y; Sakaguchi K; Fujita Y; Matsuda T; Kato M; Konishi E; Taguchi T
J Bone Miner Metab; 2018 Nov; 36(6):716-722. PubMed ID: 29116414
[TBL] [Abstract][Full Text] [Related]
9. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP
Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of denosumab for restoring normal bone mineral density in women receiving adjuvant aromatase inhibitors for early breast cancer.
Sakaguchi K; Ono H; Nakatsukasa K; Ishikawa T; Hasegawa Y; Takahashi M; Niikura N; Koizumi K; Sakurai T; Shigematsu H; Takahashi S; Taira S; Suzuki M; Narui K; Miura D; Yamada K; Yoshimura M; Shioya H; Konishi E; Isao Y; Imai K; Fujikawa K; Taguchi T;
Medicine (Baltimore); 2019 Aug; 98(32):e16770. PubMed ID: 31393399
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Gnant M; Pfeiler G; Steger GG; Egle D; Greil R; Fitzal F; Wette V; Balic M; Haslbauer F; Melbinger-Zeinitzer E; Bjelic-Radisic V; Jakesz R; Marth C; Sevelda P; Mlineritsch B; Exner R; Fesl C; Frantal S; Singer CF;
Lancet Oncol; 2019 Mar; 20(3):339-351. PubMed ID: 30795951
[TBL] [Abstract][Full Text] [Related]
12. Prevention of aromatase inhibitor-induced bone loss with anti-resorptive therapy in post-menopausal women with early-stage breast cancer.
Mugnier B; Goncalves A; Daumas A; Couderc AL; Mezni E; Viret F; de Nonneville A; Villani P
Osteoporos Int; 2023 Apr; 34(4):703-711. PubMed ID: 36715715
[TBL] [Abstract][Full Text] [Related]
13. The effects of denosumab and alendronate on glucocorticoid-induced osteoporosis in patients with glomerular disease: A randomized, controlled trial.
Iseri K; Iyoda M; Watanabe M; Matsumoto K; Sanada D; Inoue T; Tachibana S; Shibata T
PLoS One; 2018; 13(3):e0193846. PubMed ID: 29543887
[TBL] [Abstract][Full Text] [Related]
14. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.
Ellis GK; Bone HG; Chlebowski R; Paul D; Spadafora S; Smith J; Fan M; Jun S
J Clin Oncol; 2008 Oct; 26(30):4875-82. PubMed ID: 18725648
[TBL] [Abstract][Full Text] [Related]
15. Denosumab is really effective in the treatment of osteoporosis secondary to hypogonadism in prostate carcinoma patients? A prospective randomized multicenter international study.
Doria C; Leali PT; Solla F; Maestretti G; Balsano M; Scarpa RM
Clin Cases Miner Bone Metab; 2016; 13(3):195-199. PubMed ID: 28228781
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.
Gnant M; Pfeiler G; Dubsky PC; Hubalek M; Greil R; Jakesz R; Wette V; Balic M; Haslbauer F; Melbinger E; Bjelic-Radisic V; Artner-Matuschek S; Fitzal F; Marth C; Sevelda P; Mlineritsch B; Steger GG; Manfreda D; Exner R; Egle D; Bergh J; Kainberger F; Talbot S; Warner D; Fesl C; Singer CF;
Lancet; 2015 Aug; 386(9992):433-43. PubMed ID: 26040499
[TBL] [Abstract][Full Text] [Related]
17. Bone Mineral Density After Transitioning From Denosumab to Alendronate.
Kendler D; Chines A; Clark P; Ebeling PR; McClung M; Rhee Y; Huang S; Stad RK
J Clin Endocrinol Metab; 2020 Mar; 105(3):e255-64. PubMed ID: 31665314
[TBL] [Abstract][Full Text] [Related]
18. Denosumab effect on bone mineral density and urinary-NTX in breast cancer patients receiving aromatase inhibitors.
Shibata M; Okumura M; Kawano S; Noda H; Toyota C; Mizuno Y
J Bone Miner Metab; 2023 Jul; 41(4):567-574. PubMed ID: 37247110
[TBL] [Abstract][Full Text] [Related]
19. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.
Kendler DL; Roux C; Benhamou CL; Brown JP; Lillestol M; Siddhanti S; Man HS; San Martin J; Bone HG
J Bone Miner Res; 2010 Jan; 25(1):72-81. PubMed ID: 19594293
[TBL] [Abstract][Full Text] [Related]
20. Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.
Planas J; Trilla E; Raventós C; Cecchini L; Orsola A; Salvador C; Placer J; Encabo G; Morote J
BJU Int; 2009 Dec; 104(11):1637-40. PubMed ID: 19549260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]